Atlas Trials

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Clinical trial NCT05036434 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05036434
Sponsor
National Cancer Center, Korea
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Adrenocortical Carcinoma
Start date
2021-11-15
Primary completion
2027-02-28
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.